| Sep 20 |
J&J subsidiary files for bankruptcy to advance $8 billion talc settlement
|
| Sep 20 |
Johnson & Johnson Boosts Talc Settlement Payment to $8 Billion in Unit's Bankruptcy Case
|
| Sep 20 |
Johnson & Johnson unit seeks third Chapter 11 bankruptcy filing to settle talc claims
|
| Sep 20 |
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
|
| Sep 20 |
J&J unit files for bankruptcy to advance $10 billion talc settlement
|
| Sep 20 |
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
|
| Sep 20 |
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
|
| Sep 20 |
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
|
| Sep 20 |
Market Chatter: Johnson & Johnson Increases Baby Powder Settlement to $8.2 Billion, Bloomberg Reports
|
| Sep 20 |
Johnson & Johnson (NYSE:JNJ) Sees Robust Q2 Sales Growth and Strategic FDA Approvals, But Faces MedTech Challenges
|
